MyoKardia Inc logo

MYOK - MyoKardia Inc News Story

$224.91 0.0  0.0%

Last Trade - 16/11/20

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6853

MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020

Mon 2nd November, 2020 1:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201102:nGNX7ncPhC


BRISBANE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:
MYOK) today announced the upcoming presentation of clinical and non-clinical
data related to mavacamten, MyoKardia’s investigative therapeutic in
late-stage development for the potential treatment of hypertrophic
cardiomyopathy, at the upcoming American Heart Association’s Scientific
Sessions 2020.

Two of the abstracts accepted for presentation focus on echocardiographic and
cardiac magnetic resonance imaging (CMR) data from the pivotal EXPLORER-HCM
clinical trial of mavacamten. These data are expected to build on the
previously published
(https://www.globenewswire.com/Tracker?data=q2RwfguJ0t0Iw0JOY3pzyqYKQb33N7fxa8WQq1xlNci6sty5GyVTmqRKuH2s6c2Wk1gfq649yjCOimqBgtBqpkpNC5kWLZd4uYoPenezGOc9Mdmmc00EQqYI0mq-Goq-neV1eYI6dQcPT7R6Bm6fiB4TG7JkLEUvsPxoDOnvlbc=) safety
and efficacy results from the Phase 3 clinical study by providing additional
insights into changes in cardiac structure and function.

Featured Science Session: Sunday, November 15, 2020 at 3:30 p.m. CT
* Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic
Cardiomyopathy: EXPLORER-HCM CMR substudy (Oral Session 18654)
Session: High Profile Clinical Science in CVD
Lead author: Sara Saberi, M.D., University of Michigan
Available as of Friday, November 13, 2020 at 9:00 a.m. CT

ePosters on Demand
* Mavacamten Favorably Impacts Key Pathophysiologic Processes in Obstructive
Hypertrophic Cardiomyopathy: Results From the EXPLORER-HCM Study (#P1732)
Session: Different Aspects of Hypertrophic Cardiomyopathy
A 2020 Paul Dudley White Award recipient
Lead author: Sheila Hegde, M.D., Brigham and Women’s Hospital
* Accelerometer-measured Activity in Non-obstructive Hypertrophic
Cardiomyopathy: Patient-generated Activity Measures Correlate With, and are
Convolutional Neural Network Predictors of, Clinical Parameters in the
MAVERICK-HCM Study (P2047)
Session: Evaluation of Cardiac Amyloidosis and Hypertrophic Cardiomyopathy
Lead author: Euan Ashley, M.D., Stanford University Medicine
* Chronic Treatment With A Mavacamten-like Myosin-modulator (MYK-581) Prevents
Left-atrial Remodeling, Decreases Cardiac Troponin Leakage, And Blunts
Mortality In A Mini-pig Model Of Inherited Hypertrophic Cardiomyopathy (P2394)
Session: Insights from HF Clinical Tirals and Emerging Pharmacological
Therapies for Heart Failure
Lead author: Carlos del Rio, PhD, FACC, MyoKardia
Data from MyoKardia-sponsored research has also been accepted for presentation
at this year’s AHA Scientific Sessions, including the following abstracts
from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). These presentations
will also become available starting on November 13, 2020 at 9:00 a.m. CT.

ePosters on Demand: SHaRe research
* Primary Prevention Implantable Cardioverter Defibrillator Utilization for
Hypertrophic Cardiomyopathy in US vs Non-US: Findings from the Share Registry
(P1599)
Session: Advances in Cardiac Implantable Device Therapy
Lead author: Victor Nauffal, M.D., Brigham and Women’s Hospital
* The Natural History of Asymptomatic and Mildly Symptomatic Obstructive
Hypertrophic Cardiomyopathy: Insights from the Share Registry (P2380)
Session: Cardiomyopathies, arrhythmias Genomics and Mechanisms
Lead author: Monica Ahluwalia, M.D., Brigham and Women’s Hospital
About MyoKardia
MyoKardia is a clinical-stage biopharmaceutical company discovering and
developing targeted therapies for the treatment of serious cardiovascular
diseases. The company is pioneering a precision medicine approach to its
discovery and development efforts by 1) understanding the biomechanical
underpinnings of disease, 2) targeting the proteins that modulate a given
condition, 3) identifying patient populations with shared disease
characteristics and 4) applying learnings from research and clinical studies
to inform and guide pipeline growth and advancement.  MyoKardia’s initial
focus is on small molecule therapeutics aimed at the proteins of the heart
that modulate cardiac muscle contraction to address diseases driven by
excessive contraction, impaired relaxation, or insufficient contraction. Among
its discoveries are three clinical-stage therapeutics: mavacamten (formerly
MYK-461); danicamtiv (formerly MYK-491) and MYK-224. 

MyoKardia’s mission is to change the world for people with serious
cardiovascular disease through bold and innovative science.

Contacts 
Michelle Corral 
Executive Director, Corporate Communications and Investor Relations 
MyoKardia, Inc. 
650-351-4690 
ir@myokardia.com

Hannah Deresiewicz (investors) 
Stern Investor Relations, Inc. 
212-362-1200 
hannah.deresiewicz@sternir.com

Julie Normant (media)
W2O
628-213-3754
jnormart@w2ogroup.com

(https://www.globenewswire.com/NewsRoom/AttachmentNg/f2c7a5a7-d19b-4226-80bb-31c050a253fa)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.